Evidence map›Paper›PMID 20571923›Full record

Trial reportMolecular imaging and biology2011

Uptake decrease of proliferative PET tracer 18FLT in bone marrow after carbon ion therapy in lung cancer.

Mitsuru Koizumi, Tsuneo Saga, Masayuki Inubushi, Toshimitsu Fukumura, Kyosan Yoshikawa, Naoyoshi Yamamoto, Mio Nakajima, Toshio Sugane, Masayuki Baba

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Molecular imaging and biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mitsuru KoizumiDiagnostic Imaging, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. mitsuru@nirs.go.jp.
Tsuneo SagaDiagnostic Imaging, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Masayuki InubushiDiagnostic Imaging, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Toshimitsu FukumuraMolecular Probe, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Kyosan YoshikawaMolecular Imaging Center and Clinical Diagnosis Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Naoyoshi YamamotoClinical Oncology Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Mio NakajimaClinical Oncology Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Toshio SuganeClinical Oncology Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Masayuki BabaClinical Oncology Section, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to investigate the change of 3'-[¹⁸F]fluoro-3'-deoxy-L: -thymidine (¹⁸FLT) uptake in normal bone marrow (BM) after inevitable radiation. PROCEDURES: Twenty-one non-small cell lung cancer patients who received carbon ion radiotherapy (CIRT) were studied with ¹⁸FLT-positron emission tomography/computed tomography (PET/CT) at pre- and post-CIRT. Radiation dose was calculated by radiation planning. Irradiated BM was divided into three groups (<10% of maximum dose, 10-30%, and >30%).

results¹⁸FLT uptake clearly decreased at >10% irradiated areas and mildly decreased at <10% areas. ¹⁸FLT uptake was lowest just after CIRT, somewhat increased at 3 months, and remained unchanged for more than 1 year. There was no significant difference between 10-30% and >30% areas.

conclusion¹⁸FLT revealed that BM function decreased by small dose such as <4.2-4.4 GyE/1 fraction of CIRT and is eradicated by >4.2-4.4 GyE/1 fraction.

Indexed as

AgedBone MarrowCarbonCell ProliferationDemographyDideoxynucleosidesFemaleHumansIonsLumbar VertebraeLung NeoplasmsMalePositron-Emission TomographyRadiopharmaceuticalsTomography, X-Ray ComputedalovudineCarbonDideoxynucleosidesIonsRadiopharmaceuticals

Identifiers

PMID20571923

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.